Parastou Tizro | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

           Researcher Information
Researcher Parastou Tizro
Affiliation City of Hope National Cancer Center
Country United States
Scopus ID 55628206300
Documents 21
Citations 229
h-index 6
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-1928-8967
Google Scholar yhzdrIwAAAAJ&hl

Parastou Tizro

City of Hope National Cancer Center, United States

Parastou Tizro, whose work in Cancer Biology has contributed to research involving cancer mechanisms, molecular biology, and translational biomedical science. The information summarized in this article is based on publicly available academic records and bibliometric indicators.The Innovative Research Award recognizes researchers who demonstrate originality, scientific rigor, and sustained scholarly contributions within their respective disciplines. This academic profile presents an overview of.[1]

Abstract

Parastou Tizro has developed an academic profile focused on cancer biology through peer-reviewed publications, collaborative research, and contributions to biomedical science. Her research interests include molecular mechanisms of cancer, translational oncology, and related biological processes that support improved scientific understanding of disease. Bibliometric indicators demonstrate an active publication record and growing research visibility.[1][2]

Keywords

Cancer Biology, Molecular Oncology, Biomedical Research, Translational Medicine, Scientific Publications, Research Innovation, Molecular Biology, Cancer Research.

Introduction

Scientific innovation is advanced through rigorous experimentation, collaborative investigation, and the dissemination of reproducible research findings. Academic recognition considers both qualitative scientific contributions and quantitative research indicators, including publication output, citation performance, and scholarly influence across international research communities.[3]

Research Profile

  • Research affiliation with City of Hope National Cancer Center.
  • Primary specialization in Cancer Biology.
  • 21 scholarly publications indexed in Scopus.
  • 229 citations with an h-index of 6.
  • Participation in collaborative biomedical research projects.

Research Contributions

Parastou Tizro has contributed to research investigating molecular pathways associated with cancer biology and translational medicine. Her publications support scientific understanding of cancer-related biological mechanisms and emphasize evidence-based approaches to biomedical research. Collaborative studies have strengthened interdisciplinary knowledge exchange and contributed to peer-reviewed scientific literature.[2][4]

Publications

  • Twenty-one peer-reviewed publications indexed in Scopus.
  • Research addressing cancer biology and molecular biomedical science.
  • Publications cited by researchers within oncology and molecular biology disciplines.

Research Impact

Bibliometric data indicate measurable scientific influence through publication output and citation activity. Citation metrics complement qualitative assessments of originality, methodological quality, and scientific significance used during academic evaluation and recognition processes.[1][5]

Award Suitability

The available publication record, citation metrics, and ongoing scientific contributions suggest that Parastou Tizro demonstrates characteristics commonly considered during academic award evaluations. Participation in the International Molecular Biologist Awards aligns with the objective of recognizing meaningful research achievements while maintaining independent peer-review standards.[3]

Conclusion

Parastou Tizro has established a developing scholarly profile in cancer biology through scientific publications, interdisciplinary collaboration, and measurable research impact. Her academic record reflects continued engagement in biomedical research and contributes to the advancement of knowledge within molecular and cancer biology.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Parastou Tizro, Author ID 55628206300. Scopus.
    https://www.scopus.com/pages/authors/55628206300
  2. Google Scholar. (n.d.). Scholar Profile of Parastou Tizro.
    https://scholar.google.com/citations?user=yhzdrIwAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Resources.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Ching Siang Tan | Cancer Biology | Research Excellence Award

Published on by Molecular Biologist

 

Research Excellence Award

           Researcher Information
Researcher Ching Siang Tan
Affiliation KPJ Healthcare University
Country Malaysia
Scopus ID 56893025800
Documents 71
Citations 1,356
h-index 18
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0002-5069-3314
Google Scholar glKya9IAAAAJ

Ching Siang Tan

KPJ Healthcare University, Malaysia

Ching Siang Tan, whose research activities in Cancer Biology have contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and internationally indexed research outputs. The information presented follows a neutral, encyclopedic style based on publicly available academic records. The Research Excellence Award recognizes researchers who have demonstrated sustained scholarly productivity, measurable research impact, and meaningful scientific contributions within their respective disciplines. [1]

Abstract

Ching Siang Tan is a Malaysian academic researcher whose work focuses primarily on cancer biology and related biomedical sciences. His research profile includes internationally indexed publications, measurable citation impact, and collaborative scientific activities. With 71 publications, 1,356 citations, and an h-index of 18, his scholarly record reflects continued contributions to cancer research and evidence-based biomedical investigation.[1][2]

Keywords

Cancer Biology, Oncology Research, Biomedical Sciences, Scientific Publications, Citation Analysis, Molecular Medicine, Academic Research, Research Excellence.

Introduction

Cancer biology integrates molecular, cellular, genetic, and clinical research to improve the understanding of cancer initiation, progression, diagnosis, and treatment. Researchers working in this discipline contribute to scientific advancement through laboratory investigations, translational studies, and collaborative research initiatives. Bibliometric indicators such as publication output, citation counts, and the h-index provide objective measures that complement qualitative assessments of scientific achievement.[3]

Research Profile

  • Affiliated with KPJ Healthcare University, Malaysia.
  • Primary research specialization in Cancer Biology.
  • Author of 71 Scopus-indexed scholarly publications.
  • Research has received 1,356 scholarly citations.
  • Current Scopus h-index of 18.

Research Contributions

The scientific work of Ching Siang Tan encompasses investigations in cancer biology, molecular mechanisms of disease, translational biomedical research, and collaborative health sciences. His publications contribute to the growing body of knowledge supporting cancer diagnosis, therapeutic strategies, and biomedical innovation. Research dissemination through peer-reviewed journals has enhanced the accessibility and visibility of his scientific findings within the international research community.[2][4]

Publications

  • 71 peer-reviewed scholarly publications indexed in Scopus.
  • Research articles addressing cancer biology and biomedical sciences.
  • Publications cited by researchers across multiple scientific disciplines.

Research Impact

Citation-based indicators demonstrate sustained scholarly influence and scientific visibility. The combination of publication output, citation performance, and collaborative research activity reflects continuing engagement with internationally recognized research standards and contributes to the advancement of cancer biology.[1][5]

Award Suitability

Based on publicly available bibliometric information, Ching Siang Tan demonstrates characteristics commonly considered during academic award evaluations, including sustained publication activity, measurable citation impact, and continued scientific contributions in cancer biology. Such achievements align with the objectives of international academic recognition programs while remaining subject to independent expert review and evaluation.[3]

Conclusion

The academic profile of Ching Siang Tan reflects sustained engagement in cancer biology research through scholarly publications, international collaboration, and measurable citation performance. His documented research achievements provide evidence of continued contributions to biomedical science and support recognition within academic award programs that value research quality, scientific integrity, and scholarly impact.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ching Siang Tan, Author ID 56893025800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56893025800
  2. Google Scholar. (n.d.). Google Scholar Profile of Ching Siang Tan.
    https://scholar.google.com/citations?hl=en&hl=en&user=glKya9IAAAAJ
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Overview.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

 

Lucia Moraca | Cancer Biology | Women Researcher Award

Published on by Molecular Biologist

Dr. Lucia Moraca | Cancer Biology | Women Researcher Award

Medical Director | ASL FOGGIA | Italy

Dr. Lucia Moraca is a senior Italian medical oncologist specializing in medical oncology, breast cancer management, palliative care, and integrated oncology networks. She has advanced multidisciplinary cancer care, clinical governance, telemedicine, and oncology pathway organization at regional and national levels. Trained with top academic distinction, Dr. Moraca focuses on targeted therapies, immunotherapy, metastatic solid tumors, and supportive care, including cancer-related cachexia. She leads clinical risk management, pharmacovigilance, hereditary cancer programs, and innovative care models. Her research includes 9 publications, cited 109 times, demonstrating her impact in clinical oncology.

Citation Metrics (Scopus)

120

100

80

60

40

20

0

Citations
109

Documents
9

h-index
3

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Author Profile

Featured Publications

jinghui xie | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Mr. jinghui xie | Molecular Biology | Best Researcher Award 

Associate professor, at xinjiang medical university, China.

Dr. Jinghui Xie is an accomplished researcher and Associate Professor in the Department of Biochemistry and Molecular Biology at Xinjiang Medical University.  He holds a Doctor of Science (Ph.D.) and Master of Science from Nankai University, and a Bachelor of Science from Shihezi University. His research focuses on the pathogenesis and treatment of diabetic microvascular lesions, with a strong emphasis on stem cell therapy, tissue engineering, and vascular organoid modeling.  Dr. Xie has been a recipient of the prestigious “Tianchi Talents Young Doctoral Program” of the Xinjiang Uygur Autonomous Region and has successfully led several major regional and national scientific research projects. 🔬 With 6 SCI-indexed papers in top-tier international journals like Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, along with 2 impactful Chinese publications, he is making significant contributions to translational medicine. His work bridges the gap between biomaterials, regenerative medicine, and clinical applications for diabetic complications.

Professional Profile

Google Scholar

🎓 Education

Dr. Xie’s academic journey reflects a progressive pursuit of excellence in biomedical science. 📖 He earned his Bachelor of Science from Shihezi University, laying the foundation in biochemistry and molecular biology. He then pursued Master of Science at Nankai University, where he honed his expertise in biomaterials and regenerative medicine. 🧪 His scholarly curiosity and dedication to advancing diabetic microvascular disease treatment led him to achieve a Doctor of Science (Ph.D.) in Biochemistry and Molecular Biology at Nankai University. During his Ph.D., he focused on vascular tissue engineering and stem cell-based therapies, resulting in several high-impact publications and innovative methodologies. 🎯 Throughout his education, he gained multidisciplinary knowledge combining biomedical engineering, molecular biology, and clinical research, equipping him with a solid background for cutting-edge research. 🎓💡

💼 Experience

Dr. Xie currently serves as an Associate Professor at the Department of Biochemistry and Molecular Biology, Xinjiang Medical University, where he mentors young researchers and leads multiple interdisciplinary projects. 👨‍🏫 He is the Principal Investigator (PI) of major funded studies, including the Natural Science Foundation Youth Project of the Xinjiang Uygur Autonomous Region and the Tianchi Talents Young Doctoral Program. 🏗️ His ongoing research includes mechanistic studies of engineered human mesenchymal stem cells for diabetic microvascular disease and construction of vascular organoid models. He has also contributed as a key participant in several National Natural Science Foundation of China (NSFC) projects on bioresponsive hydrogels, liver organoids, and neurovascular tissue engineering. 🔬 Beyond research, Dr. Xie actively contributes to academic development through teaching, curriculum improvement, and editorial roles in medical education journals. 🏅

🔬 Research Interests

Dr. Xie’s research is deeply rooted in regenerative medicine, biomaterials, and vascular biology. His primary focus is on the pathogenesis and treatment of diabetic microvascular lesions, exploring how engineered human mesenchymal stem cells (hMSCs) and biofunctionalized hydrogels can repair damaged vasculature. 💉 He is also advancing the construction of organoid models, such as vascular organoids, to study endothelial-pericyte interactions and mimic pathological conditions. 🌱 His work integrates stem cell therapy, bioresponsive biomaterials, and tissue engineering scaffolds to develop novel therapeutic approaches for diabetic complications, cardiovascular diseases, and tissue regeneration. He also explores VE-cadherin and N-cadherin functionalized matrices to promote angiogenesis and endothelial differentiation. 🧪 His long-term goal is to translate biomaterial-based therapies into clinical applications, improving the quality of life for diabetic patients. 🌟

🏆 Awards & Honors

Dr. Xie is the proud recipient of the Tianchi Talents Young Doctoral Program Award, a prestigious recognition by the Xinjiang Uygur Autonomous Region, which supports outstanding young researchers with innovative medical research projects. 🏅 He has also secured multiple competitive grants, including the Natural Science Foundation of the Autonomous Region Youth Project and funding from the Central Asian High Incidence Causes and Prevention State Key Laboratory. 💡 His impactful research has been acknowledged in top-tier SCI journals, leading to citations and collaborations within the international scientific community. 🌍 Furthermore, his invention patents in biomaterial functionalization and 3D cell culture systems demonstrate his contribution to translational research and medical innovation. 🚀

📚 Top Noted Publications 

Dr. Xie has authored 6 SCI-indexed papers in internationally recognized journals, such as Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, and 2 additional Chinese-language articles. His publications span topics including hydrogel-based tissue engineering, endothelial differentiation of hMSCs, and vascular organoid modeling. 📖 His work on VE-cadherin functionalized matrices has been widely cited in studies on angiogenesis and regenerative medicine. ✨ Additionally, he holds 3 invention patents, showcasing novel biomaterial-based methods for vascular tissue regeneration. His research contributions have been cited in applied biomaterials, cardiovascular therapy, and diabetes-related tissue engineering studies, reinforcing his influence in the field. 🌐

🔗 Representative Publications with Citation Prompt

📄 1️⃣ Lv C, Li S, Sang M, Cui T, Xie J.
Title: Construction of Microsphere Culture System for Human Mesenchymal Stem Cell Aggregates
Journal: International Journal of Molecular Sciences
Year: 2025, Volume 26, Article 6435
Link: 🔗 Read Here
Citation Context: Frequently cited in organoid culture system research for its innovative approach to MSC aggregate formation.

📄 2️⃣ Jinghui Xie, Xiaoning Li, Yan Zhang, et al.
Title: VE-Cadherin based matrix promoting self-reconstruction of proangiogenic microenvironment
Journal: Journal of Materials Chemistry B
Year: 2021, 9(1), pp. 3357–3370
Link: 🔗 Read Here
Citation Context: Referenced in endothelial differentiation studies exploring angiogenic microenvironments.

📄 3️⃣ Yuanning Lyu, Jinghui Xie, Yang Liu, et al.
Title: Injectable Hyaluronic Acid Hydrogel for Myocardial Repair
Journal: ACS Biomaterials Science & Engineering
Year: 2020, 6(12), pp. 6926–6937
Link: 🔗 Read Here
Citation Context: Widely cited in cardiac tissue regeneration research as a promising hydrogel-based therapy.

📄 4️⃣ Yang Jun, Xie Jinghui, Gao Chao, et al.
Title: VE-cad-Fc Functionalized Hyaluronic Acid Hydrogel
Journal: Journal of Tianjin University
Year: 2019, 52(1), pp. 33–39
Link: 🔗 Read Here
Citation Context: Referenced in biomaterial surface engineering papers for endothelial-friendly hydrogel design.

📄 5️⃣ Chao Gao, Yan Zhang, Jinghui Xie, et al.
Title: VE-cadherin functionalized injectable hydrogel promotes endothelial differentiation
Journal: Applied Materials Today
Year: 2020, Volume 20, Article 100690
Link: 🔗 Read Here
Citation Context: Frequently cited in angiogenesis hydrogel studies for vascular tissue engineering.

📄 6️⃣ Ke Xu, Chuanshun Zhu, Jinghui Xie, et al.
Title: Enhanced Vascularization of PCL Scaffolds through VEGF-Fc
Journal: Journal of Materials Chemistry B
Year: 2018, 6(6), p. 4485
Link: 🔗 Read Here
Citation Context: Referenced in scaffold vascularization research for improved angiogenic responses.

🏆 Conclusion

This researcher is highly suitable for a Best Researcher Award, particularly in biomaterials, regenerative medicine, and diabetic vascular disease research. Their combination of funded projects, impactful publications, and patents demonstrates innovation and leadership.

Rongbin Li | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Rongbin Li | Cancer Biology | Best Researcher Award 

Doctorate, at Peking University, China.

Dr. Rongbin Li is a dynamic and emerging immunologist affiliated with the Department of Immunology, School of Basic Medical Sciences, and NHC Key Laboratory of Medical Immunology, Peking University, Beijing, China. He also contributes significantly to the Peking University Center for Human Disease Genomics. With a robust academic background in clinical and immunological sciences, Dr. Li’s research is focused on colitis-associated carcinogenesis and the molecular pathways that contribute to inflammatory bowel disease (IBD) and colorectal cancer. His recent milestone includes a first-author publication in the high-impact journal Cellular and Molecular Gastroenterology and Hepatology, coupled with a patent application for CMTM3 as a therapeutic target. Dr. Li has also presented his research at national congresses, underlining his capability in both lab innovation and scientific communication. His dedication to unraveling immune mechanisms promises meaningful breakthroughs in medical immunotherapy. 🌟

Professional Profile

ORCID

🎓 Education

Dr. Rongbin Li pursued his Ph.D. in Immunology at the prestigious Peking University from 2019 to 2024, focusing on medical immunology and disease genomics. His academic journey was marked by exceptional research, culminating in a first-author publication and a nationally recognized patent. Prior to this, he earned a B.Med. in Clinical Medicine from Hebei University of Engineering (2014–2019), where he was trained in clinical diagnostics, pathophysiology, and foundational immunology. His educational progression reflects a strong foundation in both theoretical knowledge and experimental methodologies. Through rigorous coursework, extensive lab work, and early exposure to clinical sciences, Dr. Li has built a dual competence in clinical medicine and molecular immunology, making him uniquely positioned to bridge the gap between bedside and bench. His multidisciplinary academic background underpins his innovative contributions to immunotherapy and cancer research. 🎓🧪

💼 Experience 

Dr. Li’s professional experience is deeply intertwined with cutting-edge immunological research at Peking University. During his doctoral tenure, he was entrusted with a National Natural Science Foundation of China (NSFC) funded project where he led experimental design, data analysis, and manuscript preparation. In collaboration with Peking University Third Hospital, he played a pivotal role in uncovering the mechanism of CMTM3 in aggravating colitis and promoting carcinogenesis, leading to a patent application. His responsibilities included conceptualization, methodology design, formal analysis, and software development, demonstrating expertise in both wet lab and computational environments. He also delivered an oral presentation at the 15th National Congress of Immunology (2023), showcasing his communication skills and subject mastery. His current research on therapeutic targets for IBD reflects a strong commitment to translational medicine. With a blend of lab skills, analytical capabilities, and cross-institutional teamwork, Dr. Li exemplifies the modern biomedical researcher. 🔬👨‍🔬

🔍 Research Interest 

Dr. Rongbin Li’s core research interest revolves around colitis-associated carcinogenesis, with a focus on the immunological and molecular interactions that promote inflammatory bowel disease (IBD) and colorectal cancer. 🧫 His primary interest lies in deciphering the role of CMTM3, a novel therapeutic target that stabilizes CLTC and disrupts VE-cadherin regulation via clathrin-mediated pathways. His ongoing work investigates how immune and endothelial interactions exacerbate inflammatory responses and facilitate tumorigenesis. He also explores the mechanistic crosstalk between inflammation and epithelial-mesenchymal transition (EMT), with the broader goal of developing CMTM3-targeted biologics or small molecules. His interdisciplinary approach combines molecular immunology, cancer biology, and vascular biology, aimed at discovering actionable targets for precision medicine. By merging bioinformatics, cellular assays, and in vivo models, Dr. Li aspires to translate fundamental immunological discoveries into clinically viable therapies, particularly for patients suffering from chronic inflammation-related cancers. 🌐🧠

🏆 Awards 

Dr. Rongbin Li’s promising contributions to immunology have garnered notable recognition. His recent work funded by the National Natural Science Foundation of China (NSFC) signifies his capability to lead and innovate in high-stakes research environments. 🧪 His first-author article in Cellular and Molecular Gastroenterology and Hepatology stands as a testament to his scholarly excellence, originality, and scientific rigor. In 2023, he was selected for an oral presentation at the 15th National Congress of Immunology, one of the most prestigious scientific forums in China. Additionally, his innovative findings led to a patent application titled “CMTM3 as a therapeutic target for IBD and colorectal cancer” (Appl. No: 2025104021503), demonstrating real-world impact and translational potential. These achievements position him as a strong candidate for the Best Researcher Award, celebrating his impactful early-career journey, commitment to scientific advancement, and potential for future breakthroughs in immunology and cancer therapy. 🏅

📚 Top Noted Publications 

Dr. Rongbin Li’s scholarly work has made a significant impact in the field of immunology. His first-author research article, published in the reputable journal Cellular and Molecular Gastroenterology and Hepatology (2025), elucidates the critical role of CMTM3 in colitis-associated carcinogenesis. The study reveals how CMTM3 stabilizes CLTC and contributes to vascular endothelial dysfunction, advancing our understanding of inflammation-driven cancer mechanisms.

Key Findings

This research identifies CMTM3 (CKLF-like MARVEL transmembrane domain-containing 3) as a significant contributor to colitis-associated colorectal cancer (CAC). The study elucidates that CMTM3 stabilizes CLTC (clathrin heavy chain), enhancing clathrin-mediated endocytosis. This process leads to the internalization and degradation of VE-Cadherin, a crucial adhesion molecule in vascular endothelial cells. The loss of VE-Cadherin disrupts endothelial integrity, increasing vascular permeability, which exacerbates colitis and fosters a pro-inflammatory environment conducive to carcinogenesis.​BioMed Central

Citation Information

As of the latest database update, this article has been cited by two other publications, indicating its emerging influence in the field of gastrointestinal oncology.​

Related Research

Previous studies have explored the role of CMTM3 in various cancers. For instance, research has shown that CMTM3 can mediate angiogenesis by regulating the cell surface availability of VE-Cadherin in endothelial adherens junctions . These findings align with the current study’s observations on CMTM3’s impact on endothelial function and its potential role in cancer progression.

Conclusion

Dr. Rongbin Li shows exceptional promise as a medical immunologist with impactful research on colitis-associated cancer, underpinned by innovation (a therapeutic patent), prestigious institutional affiliation, and peer-reviewed publication. While citation metrics and broader scholarly visibility are still developing, the quality, novelty, and translational potential of his work make him well-suited for the Best Researcher Award.